Karyopharm Therapeutics Inc. filed a current report on November 5, 2026, disclosing that Nasdaq notified the company on November 4, 2026 that its common stock will be delisted following the company's voluntary Chapter 11 bankruptcy petitions filed on November 2, 2026.

Key Highlights

  • Delisting notice received: Nasdaq staff notified Karyopharm Therapeutics on November 4, 2026 that its securities will be delisted, citing the bankruptcy petitions, public interest concerns, and doubts about the company's ability to maintain continued listing compliance.
  • Trading suspension date: Trading of the company's common stock on Nasdaq will be suspended at the opening of business on November 11, 2026.
  • No appeal planned: The company disclosed it will not appeal Nasdaq's delisting determination, which could have been pursued under Nasdaq Listing Rule 5800 Series.
  • OTC trading expected: Following delisting, the common stock is expected to trade on an over-the-counter market on or after November 11, 2026, under the symbol KPTIQ.
  • Equity holders warned of total loss: The company stated it "expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment."
  • Reorganization plan excludes equity: The Joint Prepackaged Chapter 11 Plan of Reorganization filed November 2, 2026 provides that holders of common stock and the 0% Series A Convertible Perpetual Preferred Stock "will not receive any payment or other distribution on account of such securities."

Karyopharm's Nasdaq Removal and Chapter 11 Proceedings

Karyopharm Therapeutics Inc., a Newton, Massachusetts-based biopharmaceutical company whose common stock traded on the Nasdaq Global Select Market under the ticker NASDAQ:KPTI, disclosed that it and its subsidiary KPT Texas LLC filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code on November 2, 2026, in the United States Bankruptcy Court for the Southern District of Texas, Houston Division. The delisting notice followed directly from that filing, with Nasdaq staff citing Listing Rules 5101, 5110(b) and IM-5101-1 as the basis for its determination.

According to the filing, Nasdaq's determination rested on three factors: the bankruptcy petitions themselves and associated public interest concerns; concerns regarding the residual equity interest of existing listed security holders; and concerns about the company's ability to sustain compliance with all requirements for continued listing. The company disclosed that it will not exercise its right to appeal the delisting determination. Once suspended on November 11, 2026, the shares are expected to begin trading on an over-the-counter market under the symbol KPTIQ.

The filing also references a previously disclosed stalking horse asset purchase agreement, indicating that asset sale transactions are contemplated as part of the reorganization process. The company cautioned that "trading in the Company's securities during the pendency of the Cases is highly speculative and poses substantial risks," and that trading prices on any OTC market "may bear little or no relationship to the actual recovery, if any, by the Company's securityholders." The filing contains forward-looking statements that the company identified as subject to material risks and uncertainties, including unpredictability of trading markets and the outcome of the Chapter 11 cases.

What Was Disclosed

Karyopharm Therapeutics reported receiving a Nasdaq delisting notice on November 4, 2026 following its Chapter 11 bankruptcy filing. Trading on Nasdaq will halt November 11, 2026, with OTC trading expected to follow under symbol KPTIQ. The company will not appeal.